Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NASDAQ:INSM NASDAQ:QURE NASDAQ:RARX NASDAQ:THOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$14.34-7.6%$14.63$12.79▼$55.70$1.64B1.022.23 million shs4.48 million shsINSMInsmed$144.76-0.8%$124.17$60.40▼$149.08$30.83B0.971.97 million shs5.62 million shsQUREuniQure$13.87-5.9%$15.26$4.45▼$19.18$808.74M0.141.12 million shs2.33 million shsRARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shsTHORSynthorx$67.99$67.99$11.05▼$71.90$2.20BN/A474,507 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven-7.72%+2.87%-2.22%-1.14%-63.60%INSMInsmed-0.75%-0.80%+11.83%+40.98%+98.66%QUREuniQure-5.90%-15.89%-10.40%-2.39%+140.80%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%THORSynthorx0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$14.34-7.6%$14.63$12.79▼$55.70$1.64B1.022.23 million shs4.48 million shsINSMInsmed$144.76-0.8%$124.17$60.40▼$149.08$30.83B0.971.97 million shs5.62 million shsQUREuniQure$13.87-5.9%$15.26$4.45▼$19.18$808.74M0.141.12 million shs2.33 million shsRARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shsTHORSynthorx$67.99$67.99$11.05▼$71.90$2.20BN/A474,507 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven-7.72%+2.87%-2.22%-1.14%-63.60%INSMInsmed-0.75%-0.80%+11.83%+40.98%+98.66%QUREuniQure-5.90%-15.89%-10.40%-2.39%+140.80%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%THORSynthorx0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.12Buy$51.80261.23% UpsideINSMInsmed 2.94Moderate Buy$139.86-3.39% DownsideQUREuniQure 3.00Buy$37.45170.04% UpsideRARXRa Pharmaceuticals 0.00N/AN/AN/ATHORSynthorx 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BHVN, INSM, QURE, RARX, and THOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025BHVNBiohavenCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/16/2025BHVNBiohavenUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $26.009/8/2025INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $172.009/8/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/5/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/3/2025BHVNBiohavenRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy ➝ Strong-Buy9/3/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $171.009/2/2025BHVNBiohavenRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$75.008/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/21/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$126.00 ➝ $144.008/20/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$111.00 ➝ $135.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/AINSMInsmed$363.71M84.13N/AN/A$1.60 per share90.48QUREuniQure$27.12M28.06N/AN/A($0.14) per share-99.07RARXRa Pharmaceuticals$3M757.11N/AN/A$5.56 per share8.63THORSynthorxN/AN/AN/AN/A$6.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%11/11/2025 (Estimated)INSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)RARXRa Pharmaceuticals-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/ATHORSynthorx-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/ALatest BHVN, INSM, QURE, RARX, and THOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven1.913.823.82INSMInsmed0.456.686.33QUREuniQure1.539.989.98RARXRa Pharmaceuticals0.0114.7814.79THORSynthorxN/A18.8718.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%INSMInsmedN/AQUREuniQure78.83%RARXRa PharmaceuticalsN/ATHORSynthorx66.12%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%INSMInsmed3.00%QUREuniQure4.79%RARXRa Pharmaceuticals4.30%THORSynthorx53.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239105.79 million88.86 millionOptionableINSMInsmed1,271211.38 million205.03 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableRARXRa Pharmaceuticals7247.33 millionN/AOptionableTHORSynthorx4832.34 millionN/ANot OptionableBHVN, INSM, QURE, RARX, and THOR HeadlinesRecent News About These CompaniesSanofi axes diabetes R&D, focuses on 'transformative' therapiesNovember 17, 2024 | pharmaphorum.comPDesign Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | seekingalpha.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | insidermonkey.comEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial OfficerMarch 14, 2024 | finance.yahoo.comDupixent Redux? Synthekine, Sanofi Partner on Cytokine TherapiesJanuary 29, 2024 | genengnews.comGSanofi pays Synthekine $40M to join preclinical push against vexing inflammatory targetJanuary 29, 2024 | fiercebiotech.comFEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of DirectorsDecember 19, 2023 | finance.yahoo.com‘We Have a Whole Ecosystem’: Barbara Borden Reflects on Blockbuster Horizon-Amgen Deal and Life Sciences Deals to ComeNovember 2, 2023 | law.comLPegenzileukin by Sanofi for Non-Small Cell Lung Cancer: Likelihood of ApprovalOctober 27, 2023 | pharmaceutical-technology.comPPegenzileukin by Sanofi for Squamous Cell Carcinoma: Likelihood of ApprovalJune 10, 2023 | pharmaceutical-technology.comPPegenzileukin by Sanofi for Diffuse Large B-Cell Lymphoma: Likelihood of ApprovalJune 10, 2023 | pharmaceutical-technology.comPMerck's $11B Prometheus Acquisition Brings IBD Drug & Precision ... - MedCity NewsApril 17, 2023 | news.google.comNCapstan Therapeutics Appoints Justin Thacker as Chief Financial ... - Business WireMarch 22, 2023 | news.google.comNCapstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel - Yahoo FinanceMarch 22, 2023 | news.google.comNSanofi Goes All In For Type 1 Diabetes With Provention Buy - ScripMarch 13, 2023 | news.google.comNPegenzileukin by Sanofi for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of ApprovalMarch 3, 2023 | pharmaceutical-technology.comPBridge holds firm despite placebo beating drug in midphase ... - FierceBiotechFebruary 21, 2023 | news.google.comNBiosimilar Interleukins Global Market Report 2023February 16, 2023 | uk.finance.yahoo.comReed Reaches End Of The Road As Sanofi R&D Chief - ScripFebruary 13, 2023 | news.google.comN'Robust Ecosystem' Gives Strength to San Diego's Life Science Sector - San Diego Business JournalFebruary 6, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, INSM, QURE, RARX, and THOR Company DescriptionsBiohaven NYSE:BHVN$14.34 -1.18 (-7.60%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$14.49 +0.15 (+1.05%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Insmed NASDAQ:INSM$144.76 -1.10 (-0.75%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$145.25 +0.49 (+0.34%) As of 09/19/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.uniQure NASDAQ:QURE$13.87 -0.87 (-5.90%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$14.18 +0.31 (+2.20%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Ra Pharmaceuticals NASDAQ:RARXRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Synthorx NASDAQ:THORSynthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
